Avanos Medical (NYSE:AVNS) Releases Q4 Earnings Guidance

Avanos Medical (NYSE:AVNS) updated its fourth quarter earnings guidance on Monday. The company provided EPS guidance of $0.38-0.43 for the period, compared to the consensus EPS estimate of $0.40. The company issued revenue guidance of $175-180 million, compared to the consensus revenue estimate of $177.25 million.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Price Performance

Shares of NYSE AVNS traded up $0.69 during midday trading on Monday, reaching $15.89. The company’s stock had a trading volume of 288,264 shares, compared to its average volume of 796,176. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The company has a market cap of $730.26 million, a P/E ratio of 46.74 and a beta of 0.99. The business’s 50 day moving average price is $17.84 and its two-hundred day moving average price is $20.93. Avanos Medical has a fifty-two week low of $14.98 and a fifty-two week high of $25.36.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.